Akoya (AKYA) Reports In-Line Q2 EPS, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Morgan Stanley Downgrades Akoya Biosciences Inc (AKYA) to Equalweight
August 6, 2024 12:06 PM EDTMorgan Stanley analyst Tejas Savant downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Overweight to Equalweight with a price target of $3.00 (from $4.00).
The analyst comments "Guide lowered again despite in-line qtr as placements rebound falls short of expectations on weak capital... More
BTIG Downgrades Akoya Biosciences Inc (AKYA) to Neutral
August 6, 2024 6:02 AM EDTBTIG analyst Mark Massaro downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Buy to Neutral.
The analyst comments "AKYA announced its third workforce reduction in 13 months, and lowered its 2024 revenue guidance in back-to-back quarters. Investor concerns have ranged from constrained budgets in the... More



